Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class ASSE: 688266

Announcement on Voluntary Disclosure of Clinical Data and Latest Progress of ZG005 and ZG006 Released at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 2, 2026 · Issued by Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A via Shanghai Stock Exchange

Announcement on Voluntary Disclosure of Clinical Data and Latest Progress of ZG005 and ZG006 Released at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Company analysis

Earlier from Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A

Announcement on Voluntary Disclosure of Phase III Clinical Trial of Recombinant Human Thyrotropin β for Injection Reaching Prespecified Primary EndpointMay 8
Announcement on Change of Accounting PoliciesApr 29
Science and Technology for People's Well-being - Achievement of Enterprises on SSE STAR Market and Its Empowerment of People's Livelihood ConferenceApr 24

All Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A news releases